Compare AbCellera Biologics Inc (ABCL) vs Newegg Commerce Inc (NEGG) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

NEGG trades at $14.94 with minimal daily movement (+0.2%). The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment. Recent financials reveal modest revenue growth to $1.44B in 2025, though profitability remains challenged with a net loss of $4.88M. The company is investing in AI shopping experiences and promotional events to drive growth.

While analyst consensus is bullish (100% buy rating), fundamental weaknesses including negative cash flow from operations and thin margins present risks. The stock's valuation appears stretched with a P/E of 57.14, suggesting limited near-term upside without significant earnings improvement.